ArticleMetabolic brain disease2026
MS-based metabolic profiling in serum for bipolar disorder.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBipolar disorder (BD) is a chronic psychiatric illness characterized by alternating episodes of mania and depression. Diagnostic challenges arise from the subjective nature of clinical assessments, often leading to delayed or inaccurate treatment. The identification of objective biomarkers specific to BD may improve diagnostic accuracy and enable early intervention. This study aimed to analyze serum metabolomic profiles of BD patients during euthymic and manic states to identify potential diagnostic and predictive biomarkers.
methodsSerum samples were collected from 33 patients in the manic phase, 25 patients in the euthymic phase, and 40 healthy controls. Samples were analyzed using high-resolution liquid chromatography-mass spectrometry. Metabolite levels were determined semi-quantitatively. The identified metabolic features were analysed using univariate statistics, confounder-adjusted logistic regression, and multivariate and pathway enrichment approaches.
resultsComparisons between patients with BD and healthy controls revealed alterations primarily in lipid-related metabolites, including primary fatty acid amides, phosphatidylcholine derivatives, and acylcarnitines. Following adjustment, oleamide and 2-arachidonoylglycerol were found to be significantly associated with the euthymic state relative to the control group. In manic patients, several lipid metabolites exhibited consistent directional changes compared to the control group, although most of these associations did not survive multiple testing correction. Direct comparison between the manic and euthymic states identified a limited number of metabolites, suggesting metabolic differences related to the state.
conclusionThis exploratory serum metabolomics study has identified subtle yet biologically plausible metabolic alterations associated with bipolar disorder and its mood states. The findings emphasise the importance of lipid metabolism and mitochondrial energy pathways in the pathophysiology of BD, while also highlighting the influence of mood state. Although the results are preliminary and require validation in larger, longitudinal cohorts that are preferably drug-naïve, they lay the groundwork for future targeted metabolomic studies aimed at clarifying state- and disease-related metabolic signatures in BD.
Indexed as
Identifiers
42463587What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.